NASDAQ:SNOA - Nasdaq - US83558L3033 - Common Stock - Currency: USD
NASDAQ:SNOA (4/23/2025, 10:25:08 AM)
3.8789
+1.55 (+66.48%)
The current stock price of SNOA is 3.8789 USD. In the past month the price decreased by -27.86%. In the past year, price decreased by -26.73%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 64.38 | 793.43B | ||
JNJ | JOHNSON & JOHNSON | 15.56 | 376.89B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 17.83 | 276.21B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.9 | 218.06B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.62 | 213.83B | ||
MRK | MERCK & CO. INC. | 10.45 | 200.96B | ||
PFE | PFIZER INC | 7.33 | 129.37B | ||
SNY | SANOFI-ADR | 11.69 | 129.06B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 42.84 | 99.38B | ||
GSK | GSK PLC-SPON ADR | 8.5 | 75.25B | ||
ZTS | ZOETIS INC | 25.84 | 68.24B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.52 | 48.11B |
Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Boulder, Colorado and currently employs 172 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
SONOMA PHARMACEUTICALS INC
5445 Conestoga Court, Suite 150
Boulder COLORADO 30189 US
CEO: Amy Trombly
Employees: 172
Company Website: https://sonomapharma.com/
Investor Relations: http://ir.oculusis.com/
Phone: 18007599305
The current stock price of SNOA is 3.8789 USD. The price increased by 66.48% in the last trading session.
The exchange symbol of SONOMA PHARMACEUTICALS INC is SNOA and it is listed on the Nasdaq exchange.
SNOA stock is listed on the Nasdaq exchange.
7 analysts have analysed SNOA and the average price target is 17.34 USD. This implies a price increase of 347.03% is expected in the next year compared to the current price of 3.8789. Check the SONOMA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SONOMA PHARMACEUTICALS INC (SNOA) has a market capitalization of 6.28M USD. This makes SNOA a Nano Cap stock.
SONOMA PHARMACEUTICALS INC (SNOA) currently has 172 employees.
SONOMA PHARMACEUTICALS INC (SNOA) has a support level at 2.21 and a resistance level at 2.34. Check the full technical report for a detailed analysis of SNOA support and resistance levels.
The Revenue of SONOMA PHARMACEUTICALS INC (SNOA) is expected to grow by 5.59% in the next year. Check the estimates tab for more information on the SNOA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SNOA does not pay a dividend.
SONOMA PHARMACEUTICALS INC (SNOA) will report earnings on 2025-06-16, after the market close.
SONOMA PHARMACEUTICALS INC (SNOA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.96).
The outstanding short interest for SONOMA PHARMACEUTICALS INC (SNOA) is 0.61% of its float. Check the ownership tab for more information on the SNOA short interest.
ChartMill assigns a fundamental rating of 3 / 10 to SNOA. No worries on liquidiy or solvency for SNOA as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -3.96. The EPS decreased by -59.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -27.42% | ||
ROE | -76.96% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to SNOA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 24.72% and a revenue growth 5.59% for SNOA